Related Experiment Video
Updated: May 10, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1
Ting C Zhao1, Jianfeng Du, Shougang Zhuang
1Cardiovascular Research laboratory, Department of Surgery, Roger Williams Medical Center, Boston University Medical School, Providence, Rhode Island, United States of America. tzhao@bu.edu
Insights
Histone deacetylase (HDAC) inhibition protects the heart. This study shows that MKK3 and Akt-1 pathways are crucial for HDAC inhibition-induced cardioprotection against ischemia-reperfusion injury.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Pharmacology
Background:
- Histone deacetylase (HDAC) inhibition is known to protect the heart from injury.
- Akt-1 and MAP kinase are critical for myocardial protection and cardiac preconditioning.
- Previous work showed Akt-1 activation post-myocardial infarction following HDAC inhibition.
Purpose of the Study:
- To investigate if MKK3 and Akt-1 are involved in HDAC inhibition-induced cardioprotection during acute myocardial ischemia and reperfusion.
- To determine if genetic disruption of Akt-1 and MKK3 eliminates HDAC inhibition-induced cardioprotection.
- To explore the association between Akt-1 and MKK3 in achieving protective effects.
Main Methods:
- Adult wild-type, MKK3 knockout, and Akt-1 knockout mice were used.
- Pharmacologic preconditioning was induced using trichostatin A (HDAC inhibitor).
- Hearts underwent ischemia/reperfusion injury; left ventricular function and infarct size were assessed.
Main Results:
- HDAC inhibition improved left ventricular functional recovery and reduced infarct size.
- Disruption of Akt-1 or MKK3 abrogated these protective effects.
- Akt-1 disruption abolished MKK3 acetylation and phosphorylation; Trichostatin A increased MKK3 phosphorylation/acetylation.
Conclusions:
- The MKK3 and Akt-1 pathway is essential for HDAC inhibition-induced cardioprotection.
- Targeting the MKK3-Akt-1 pathway represents a novel strategy for mitigating myocardial injury.
Abstract:
We and others have demonstrated that HDAC inhibition protects the heart against myocardial injury. It is known that Akt-1 and MAP kinase play an essential role in modulation of myocardial protection and cardiac preconditioning. Our recent observations have shown that Akt-1 was activated in post-myocardial infarction following HDAC inhibition. However, it remains unknown whether MKK3 and Akt-1 are involved in HDAC inhibition-induced myocardial protection in acute myocardial ischemia and reperfusion injury. We sought to investigate whether the genetic disruption of Akt-1 and MKK3 eliminate cardioprotection elicited by HDAC inhibition and whether Akt-1 is associated with MKK3 to ultimately achieve protective effects. Adult wild type and MKK3⁻/⁻, Akt-1⁻/⁻ mice received intraperitoneal injections of trichostatin A (0.1 mg/kg), a potent inhibitor of HDACs. The hearts were subjected to 30 min myocardial ischemia/30 min reperfusion in the Langendorff perfused heart after twenty four hours to elicit pharmacologic preconditioning. Left ventricular function was measured, and infarct size was determined. Acetylation and phosphorylation of MKK3 were detected and disruption of Akt-1 abolished both acetylation and phosphorylation of MKK3. HDAC inhibition produces an improvement in left ventricular functional recovery, but these effects were abrogated by disruption of either Akt-1 or MKK3. Disruption of Akt-1 or MKK3 abolished the effects of HDAC inhibition-induced reduction of infarct size. Trichostatin A treatment resulted in an increase in MKK3 phosphorylation or acetylation in myocardium. Taken together, these results indicate that stimulation of the MKK3 and Akt-1 pathway is a novel approach to HDAC inhibition -induced cardioprotection.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy III: Hypertrophic Cardiomyopathy
The JAK-STAT Signaling Pathway
Myocarditis III: Medical Management
PI3K/mTOR/AKT Signaling Pathway